BeiGene, Ltd. (ONC)vsProtagonist Therapeutics Inc (PTGX)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
PTGX
Protagonist Therapeutics Inc
$104.31
+3.90%
HEALTHCARE · Cap: $6.66B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 11511% more annual revenue ($5.34B vs $46.02M). ONC leads profitability with a 5.4% profit margin vs -282.8%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
PTGX
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for PTGX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Earnings expanding 351.3% YoY
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Trading at 10.6x book value
ROE of -20.2% — below average capital efficiency
Revenue declined 95.6%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : PTGX
The strongest argument for PTGX centers on EPS Growth.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : PTGX
The primary concerns for PTGX are Price/Book, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while PTGX is a turnaround play — different risk/reward profiles.
PTGX carries more volatility with a beta of 2.24 — expect wider price swings.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Bottom Line
ONC scores higher overall (42/100 vs 28/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Protagonist Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?